Atara Biotherapeutics Plummets After FDA Response
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy ATRA?
Atara Biotherapeutics Inc's shares dropped 54% to $6.24, hitting a 20-day low, following the receipt of an FDA Complete Response Letter citing concerns over clinical trial adequacy.
The FDA's Complete Response Letter indicates that Atara's clinical trials may not have met the necessary standards, which could lead to significant financial and operational challenges for the company. This news has contributed to a sharp decline in investor confidence, resulting in a substantial drop in the stock price amid broader market weakness.
The implications of this FDA response are severe, as it not only affects Atara's current projects but also raises questions about future developments and investor trust in the company's ability to navigate regulatory hurdles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.270
Low
18.00
Averages
21.50
High
25.00
Current: 5.270
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for Atara Biotherapeutics Investors on Class Action Deadline
- FDA Regulatory Crisis: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its Biologics License Application for EBVALLO was not approved, causing a 40.5% drop in stock price to $7.83 per share, severely impacting investors.
- Clinical Trial Hold: On January 21, 2025, Atara disclosed that the FDA placed a clinical hold on its active IND applications due to GMP compliance issues found during inspections, leading to a further 7.9% decline in stock price to $6.05 per share, exacerbating investor losses.
- Another CRL Issued: On January 12, 2026, Atara disclosed another Complete Response Letter from the FDA stating that the EBVALLO application could not be approved due to trial design issues, resulting in a 56.99% drop in stock price to $5.88 per share, increasing risks for investors.
- Class Action Initiated: A class action lawsuit has been initiated against Atara for failing to disclose manufacturing issues and clinical trial deficiencies throughout the class period, misleading investors about the company's prospects, with a deadline for lead plaintiff motions set for May 22, 2026.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the truth emerged, likely having a significant negative impact on the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first in 2017 for the number of settlements, demonstrating its expertise in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting a law firm with a successful track record to ensure optimal representation and support in the class action.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the regulatory prospects of the tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure optimal representation in litigation and avoid firms that merely act as intermediaries.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, including manufacturing issues and deficiencies in the ALLELE study, which may hinder FDA approval of the tabelecleucel Biologics License Application.
- Increased Regulatory Risks: The aforementioned manufacturing issues expose Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant negative impact on the company's financial condition, exacerbating the risk of investor losses.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to help investors understand their rights and potential legal options.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, highlighting serious concerns regarding the company's transparency and investor communication.
- Regulatory Scrutiny Risks: The lawsuit alleges that Atara misled investors about the regulatory prospects of its lead drug candidate, tabelecleucel, particularly due to manufacturing issues and deficiencies in the ALLELE study, making FDA approval unlikely and exposing the company to heightened regulatory scrutiny.
- Stock Price Plunge Impact: Following a press release on January 12, 2026, announcing that the FDA issued a Complete Response Letter regarding tabelecleucel, Atara's stock price plummeted by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, indicating the importance of corporate governance and shareholder rights in the wake of potential mismanagement issues.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The complaint claims that Atara faced manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for tabelecleucel, thereby increasing regulatory scrutiny and jeopardizing ongoing clinical trials.
- Financial Impact: These issues are likely to have a significant negative impact on Atara's business and financial condition, rendering the company's public statements materially false or misleading during the relevant period.
- Investor Action: Affected investors have until May 22, 2026, to request lead plaintiff status, with the law firm representing investors on a contingency fee basis, only charging if successful.
See More
Reminder for Atara Biotherapeutics Investors on Class Action Deadline
- FDA Regulatory Crisis: On January 16, 2025, Atara received a Complete Response Letter from the FDA indicating that its Biologics License Application for EBVALLO was not approved, causing a 40.5% drop in stock price to $7.83 per share, severely impacting investors.
- Clinical Trial Hold: On January 21, 2025, Atara disclosed that the FDA placed a clinical hold on its active IND applications due to GMP compliance issues found during inspections, leading to a further 7.9% decline in stock price to $6.05 per share, exacerbating investor losses.
- Another CRL Issued: On January 12, 2026, Atara disclosed another Complete Response Letter from the FDA stating that the EBVALLO application could not be approved due to trial design issues, resulting in a 56.99% drop in stock price to $5.88 per share, increasing risks for investors.
- Class Action Initiated: A class action lawsuit has been initiated against Atara for failing to disclose manufacturing issues and clinical trial deficiencies throughout the class period, misleading investors about the company's prospects, with a deadline for lead plaintiff motions set for May 22, 2026.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the truth emerged, likely having a significant negative impact on the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first in 2017 for the number of settlements, demonstrating its expertise in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting a law firm with a successful track record to ensure optimal representation and support in the class action.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, to apply as lead plaintiffs by May 22, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and deficiencies in the ALLELE study, which overstated the regulatory prospects of the tabelecleucel Biologics License Application, significantly impacting the company's financial condition.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its extensive experience and success in this field.
- Investor Guidance: Investors are advised to be cautious when selecting legal counsel, with Rosen Law Firm recommending choosing attorneys with proven success in class actions to ensure optimal representation in litigation and avoid firms that merely act as intermediaries.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California, targeting investors who purchased Atara securities between May 20, 2024, and January 9, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements and failed to disclose critical adverse facts regarding its business and operations, including manufacturing issues and deficiencies in the ALLELE study, which may hinder FDA approval of the tabelecleucel Biologics License Application.
- Increased Regulatory Risks: The aforementioned manufacturing issues expose Atara to heightened regulatory scrutiny, which not only jeopardizes ongoing clinical trials but also poses a significant negative impact on the company's financial condition, exacerbating the risk of investor losses.
- Investor Action Call: Affected investors are encouraged to apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to help investors understand their rights and potential legal options.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, highlighting serious concerns regarding the company's transparency and investor communication.
- Regulatory Scrutiny Risks: The lawsuit alleges that Atara misled investors about the regulatory prospects of its lead drug candidate, tabelecleucel, particularly due to manufacturing issues and deficiencies in the ALLELE study, making FDA approval unlikely and exposing the company to heightened regulatory scrutiny.
- Stock Price Plunge Impact: Following a press release on January 12, 2026, announcing that the FDA issued a Complete Response Letter regarding tabelecleucel, Atara's stock price plummeted by 56.99% to close at $5.88 per share, reflecting market pessimism about the company's future prospects.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by May 22, 2026, indicating the importance of corporate governance and shareholder rights in the wake of potential mismanagement issues.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Atara Biotherapeutics, alleging violations of federal securities laws on behalf of all investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The complaint claims that Atara faced manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for tabelecleucel, thereby increasing regulatory scrutiny and jeopardizing ongoing clinical trials.
- Financial Impact: These issues are likely to have a significant negative impact on Atara's business and financial condition, rendering the company's public statements materially false or misleading during the relevant period.
- Investor Action: Affected investors have until May 22, 2026, to request lead plaintiff status, with the law firm representing investors on a contingency fee basis, only charging if successful.
See More
